Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
547 hedge funds and large institutions have $42.4B invested in Alexion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 75 funds opening new positions, 206 increasing their positions, 190 reducing their positions, and 37 closing their positions.
103% more first-time investments, than exits
New positions opened: 75 | Existing positions closed: 37
21% more capital invested
Capital invested by funds: $34.9B → $42.4B (+$7.5B)
11% more funds holding in top 10
Funds holding in top 10: 19 → 21 (+2)
7% more funds holding
Funds holding: 513 → 547 (+34)
8% more repeat investments, than reductions
Existing positions increased: 206 | Existing positions reduced: 190
5% less call options, than puts
Call options by funds: $168M | Put options by funds: $177M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$112M |
| 2 |
Jennison Associates
New York
|
+$84M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$62.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$61.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$59.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$122M |
| 2 |
Renaissance Technologies
New York
|
-$108M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$81.9M |
| 4 |
Morgan Stanley
New York
|
-$69.6M |
| 5 |
HM
HealthCor Management
New York
|
-$68.1M |
ALXN Hedge Fund Activity: Q4 2015 in Review
547 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2015, worth a combined $42.4B — up 21% from $34.9B a quarter earlier.
Buyers outnumbered sellers: 75 funds opened new ALXN positions and 37 closed out — a net gain of 38 holders — while 206 added to existing stakes and 190 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $112M. The largest seller was Thrivent Financial for Lutherans, cutting an estimated $122M.
- 547 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2015, up from 513 in Q3 2015.
- Funds reported $42.4B of Alexion Pharmaceuticals stock for Q4 2015, up 21% quarter-over-quarter.
- 75 funds opened new Alexion Pharmaceuticals positions in Q4 2015 and 37 closed out, a net change of +38 holders.
- The largest Alexion Pharmaceuticals buyer in Q4 2015 was AllianceBernstein, an estimated $112M added.
- The largest Alexion Pharmaceuticals seller in Q4 2015 was Thrivent Financial for Lutherans, an estimated $122M sold.
Based on aggregated 13F filings for Q4 2015.